Torrent C, Amann B, Sánchez-Moreno J, Colom F, Reinares M, Comes M, Rosa A R, Scott J, Vieta E
Bipolar Disorders Program, Clinical Institute of Neuroscience, University Hospital Clinic, University of Barcelona, IDIBAPS, CIBER-SAM, Barcelona, Spain.
Acta Psychiatr Scand. 2008 Jul;118(1):4-18. doi: 10.1111/j.1600-0447.2008.01204.x. Epub 2008 May 22.
The aim of this paper was to review the association of most commonly used psychopharmacological drugs with weight gain in bipolar disorder.
Information was retrieved from a PubMed/Medline literature search reviewing weight gain in pharmacological studies in bipolar disorder.
Obesity and overweight in bipolar disorder are partly related to prescribed drugs with a strong effect of clozapine and olanzapine. Lesser but still relevant weight gain is caused by quetiapine, risperidone, lithium, valproate, gabapentin and by some antidepressants. Ziprasidone, aripiprazole, carbamazepine and lamotrigine do not seem to cause significant overweight.
Careful monitoring of weight changes in patients before and after drug prescription should be implemented in the clinical routine and drugs which potentially cause weight gain should be avoided in overweight patients with bipolar disorder. Furthermore, eating habits and daily activities should be targeted as they may also have a significant impact on overall health and weight-related issues.
本文旨在综述双相情感障碍中最常用的精神药物与体重增加之间的关联。
通过PubMed/Medline文献检索获取有关双相情感障碍药理学研究中体重增加情况的信息。
双相情感障碍中的肥胖和超重部分与所开药物有关,氯氮平和奥氮平的影响较大。喹硫平、利培酮、锂盐、丙戊酸盐、加巴喷丁以及一些抗抑郁药导致的体重增加较少但仍具有相关性。齐拉西酮、阿立哌唑、卡马西平和拉莫三嗪似乎不会导致明显超重。
临床常规中应仔细监测患者用药前后的体重变化,双相情感障碍超重患者应避免使用可能导致体重增加的药物。此外,饮食习惯和日常活动也应作为目标,因为它们可能对整体健康和体重相关问题产生重大影响。